Hard to Treat Diseases (Hard to Treat Diseases) Revenue : $ Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases Revenue?

Hard to Treat Diseases's revenue for the three months ended in . 20 was $0.00 Mil. Hard to Treat Diseases does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in . 20. Hard to Treat Diseases's Revenue per Share for the three months ended in . 20 was $0.00. Hard to Treat Diseases does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Hard to Treat Diseases Revenue Historical Data

The historical data trend for Hard to Treat Diseases's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases Revenue Chart

Hard to Treat Diseases Annual Data

Trend

Revenue

Hard to Treat Diseases Quarterly Data

Revenue

Competitive Comparison of Hard to Treat Diseases's Revenue

For the Biotechnology subindustry, Hard to Treat Diseases's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hard to Treat Diseases's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's Revenue distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's Revenue falls into.

Hard to Treat Diseases Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Hard to Treat Diseases (OTCPK:HTDS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Hard to Treat Diseases Revenue Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hard to Treat Diseases (Hard to Treat Diseases) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762

Website

http://www.htdsmedical.com

Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases (Hard to Treat Diseases) Headlines

No Headlines